Transferring the financial risks of pharmaceutical benefits from a large health care provider in Argentina to a consortium of pharmaceutical companies

Bibliographic Data

ID14967504
AuthorsJuan C Cervellino (corresponding author), Sandra B Corazza (Universidad de Buenos Aires), Inés M I Bignone, I Bignone (Universidad de Buenos Aires), M Diana Fligman (Universidad de Buenos Aires), Silvana Figueroa, Santos Andrés Gutiérrez Figueroa (0009-0004-6821-7406, Universidad de Buenos Aires), Rubén Roldán, Pablo Morici, Roberto A Diez (0000-0002-2452-9166, Universidad de Buenos Aires)
Year2003
Volume13
Issue4
Pages203-213
Publication date2003-04-01
Open AccessYes
TypeARTICLE
VenueRevista Panamericana de Salud Pública (JOURNAL)
Journal identifiersISSN: 1020-4989 • E-ISSN: 1680-5348
PublisherFapUNIFESP (SciELO) (PUBLISHER)
DOI10.1590/s1020-49892003000300002
PMID12804149
OpenAlexW2048645982
SciELOS1020-49892003000300002
LanguageEN
Citations received3
References cited1

An agreement with pharmaceutical companies, like the one we have described, might add an element of financial predictability for institutions such as the NISSRP. However, such an agreement can easily result in an increased economic burden for health care beneficiaries, and without any improvement in the services that they receive. This type of agreement requires extensive mechanisms for control, follow-up, and updating, and it also risks making nonrational drug prescribing the accepted rule. While perhaps feasible, the requirements for this kind of agreement are actually very difficult to put into place, requiring additional efforts from institutions such as the NISSRP

Agency (philosophy · Business · Consumption (sociology · Economic growth · Economics · Fiscal year · Health care · Payment · Healthcare Policy and Management · Healthcare Systems and Reforms · Medicine · Public Health in Brazil · Finance

Tools

Open DOIOpen Access